276 related articles for article (PubMed ID: 34952776)
1. Disease burden of respiratory syncytial virus infection in the pediatric population in Japan.
Nagasawa K; Ishiwada N
J Infect Chemother; 2022 Feb; 28(2):146-157. PubMed ID: 34952776
[TBL] [Abstract][Full Text] [Related]
2. Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan.
Kusuda S; Takahashi N; Saitoh T; Terai M; Kaneda H; Kato Y; Ohashi A; Watabe S; Joh-o K; Hirai K
Pediatr Int; 2011 Jun; 53(3):368-73. PubMed ID: 20854284
[TBL] [Abstract][Full Text] [Related]
3. Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia.
Ordóñez JE; Huertas VM
BMC Infect Dis; 2024 Apr; 24(1):418. PubMed ID: 38641577
[TBL] [Abstract][Full Text] [Related]
4. Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.
Forbes ML; Kumar VR; Yogev R; Wu X; Robbie GJ; Ambrose CS
Hum Vaccin Immunother; 2014; 10(10):2789-94. PubMed ID: 25483663
[TBL] [Abstract][Full Text] [Related]
5. Respiratory syncytial virus hospitalizations in infants of 28 weeks gestational age and less in the palivizumab era.
Resch B; Egger B; Kurath-Koller S; Urlesberger B
Int J Infect Dis; 2017 Apr; 57():50-53. PubMed ID: 28163166
[TBL] [Abstract][Full Text] [Related]
6. Systematic Review of the Safety and Efficacy of Palivizumab among Infants and Young Children with Cystic Fibrosis.
Kua KP; Lee SWH
Pharmacotherapy; 2017 Jun; 37(6):755-769. PubMed ID: 28423192
[TBL] [Abstract][Full Text] [Related]
7. Palivizumab prophylaxis of respiratory syncytial virus disease from 1998 to 2002: results from four years of palivizumab usage.
Romero JR
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S46-54. PubMed ID: 12671452
[TBL] [Abstract][Full Text] [Related]
8. Palivizumab prophylaxis against respiratory syncytial virus infection in patients younger than 2 years of age with congenital heart disease.
Mohammed MHA; Agouba R; Obaidy IE; Alhabshan F; Abu-Sulaiman R
Ann Saudi Med; 2021; 41(1):31-35. PubMed ID: 33550912
[TBL] [Abstract][Full Text] [Related]
9. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
10. Palivizumab prophylaxis in preterm infants and subsequent wheezing/asthma: 10-year follow-up study.
Kato M; Mochizuki H; Kama Y; Kusuda S; Okada K; Yoshihara S; Furuya H; Simões EAF;
Pediatr Pulmonol; 2024 Mar; 59(3):743-749. PubMed ID: 38116923
[TBL] [Abstract][Full Text] [Related]
11. Effect of delayed palivizumab administration on respiratory syncytial virus infection-related hospitalisation: A retrospective, observational study.
Kamori A; Morooka Y; Yamamura K; Chong PF; Kuga N; Takahata Y; Sagawa K; Furuno K
Medicine (Baltimore); 2021 Nov; 100(47):e27952. PubMed ID: 34964779
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
[TBL] [Abstract][Full Text] [Related]
13. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection.
;
Pediatrics; 2014 Aug; 134(2):415-20. PubMed ID: 25070315
[TBL] [Abstract][Full Text] [Related]
14. Cost-utility analysis of Palivizumab for Respiratory Syncytial Virus infection prophylaxis in preterm infants: update based on the clinical evidence in Spain.
Sanchez-Luna M; Burgos-Pol R; Oyagüez I; Figueras-Aloy J; Sánchez-Solís M; Martinón-Torres F; Carbonell-Estrany X
BMC Infect Dis; 2017 Oct; 17(1):687. PubMed ID: 29041909
[TBL] [Abstract][Full Text] [Related]
15. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
Wang D; Bayliss S; Meads C
Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
[TBL] [Abstract][Full Text] [Related]
16. Survey of hospitalization for respiratory syncytial virus in Nagano, Japan.
Yanagisawa T; Nakamura T
Pediatr Int; 2018 Sep; 60(9):835-838. PubMed ID: 29923346
[TBL] [Abstract][Full Text] [Related]
17. Palivizumab for respiratory syncytial virus prophylaxis in high-risk infants: a cost-effectiveness analysis.
Lofland JH; O'Connor JP; Chatterton ML; Moxey ED; Paddock LE; Nash DB; Desai SA
Clin Ther; 2000 Nov; 22(11):1357-69. PubMed ID: 11117660
[TBL] [Abstract][Full Text] [Related]
18. Respiratory syncytial virus (RSV) infection in children with medical complexity.
Lim A; Butt ML; Dix J; Elliott L; Paes B
Eur J Clin Microbiol Infect Dis; 2019 Jan; 38(1):171-176. PubMed ID: 30374685
[TBL] [Abstract][Full Text] [Related]
19. Palivizumab Prophylaxis among Infants at Increased Risk of Hospitalization due to Respiratory Syncytial Virus Infection in UAE: A Hospital-Based Study.
Elhalik M; El-Atawi K; Dash SK; Faquih A; Satyan AD; Gourshettiwar N; Khan A; Varughese S; Ramesh A; Khamis E
Can Respir J; 2019; 2019():2986286. PubMed ID: 31871513
[TBL] [Abstract][Full Text] [Related]
20. Study protocol: a multicenter, uncontrolled, open-label study of palivizumab in neonates, infants, and preschool children at high risk of severe respiratory syncytial virus infection.
Mori M; Watabe S; Taguchi T; Hasegawa H; Ishige M; Tanuma N; Hirakawa A; Koike R; Kusuda S
BMC Pediatr; 2021 Mar; 21(1):106. PubMed ID: 33653291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]